Filing Details

Accession Number:
0001225208-25-001686
Form Type:
4
Zero Holdings:
No
Publication Time:
2025-02-13 16:32:50
Reporting Period:
2025-02-11
Filing Date:
2025-02-13
Accepted Time:
2025-02-13 16:32:50
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
885725 Boston Scientific Corp BSX Surgical & Medical Instruments & Apparatus (3841) 042695240
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1629277 Bradley John Sorenson 300 Boston Scientific Way
Marlborough MA 01752-1234
Evp, Global Operations No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2025-02-11 10,182 $0.00 36,631 No 4 A Direct
Common Stock Disposition 2025-02-11 3,793 $105.98 32,838 No 4 F Direct
Common Stock Disposition 2025-02-12 2,156 $0.00 30,682 No 4 G Direct
Common Stock Disposition 2025-02-12 6,389 $105.06 24,293 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 F Direct
No 4 G Direct
No 4 S Direct
Footnotes
  1. On February 16, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2024 and subject to the completion of the concurrent three-year individual service period. On February 11, 2025, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.
  2. The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.
  3. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $104.81 to $105.26, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.